ALK's Q1 better than predicted on top and bottom line

Allergy firm ALK upgrades its financial outlook for the rest of the year following a first quarter that exceeded expectations.

Photo: ALK / PR

Danish pharmaceutical company ALK managed to do better than predicted in the first three months of the year measured by income as well as revenue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs